Tech Company Financing Transactions

iPierian Funding Round

iPierian, based in South San Francisco, secured $30 million from Kleiner Perkins Caufield & Byers, MPM Capital and SR One Capital Management.

Transaction Overview

Company Name
iPierian
Announced On
9/4/2013
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors

Kleiner Perkins Caufield & Byers (Lead Investor) (Beth Seidenberg)

MPM Capital (Lead Investor) (James Scopa)

SR One Capital Management (Lead Investor) (Rajeev Dadoo)

Atel Ventures

GV (Krishna Yeshwant)

Highland Capital Partners (Robert Higgins)

Mitsubishi Corporation

Proceeds Purpose
For iPierian, proceeds of the financing will be used to accelerate the clinical development program for IPN007, a monoclonal antibody targeting the Tau protein for the treatment of Alzheimer's disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia). iPierian selected IPN007 based on novel secreted Tau discoveries made using its induced pluripotent stem cell (iPSC) platform.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
951 Gateway Blvd
South San Francisco, CA 94080
USA
Phone
(650) 872-4700
Website
www.ipierian.com
Email Address
[email protected]
Overview
iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
Profile
iPierian LinkedIn Company Profile
Social Media
iPierian Company Twitter Account
Company News
iPierian News
Facebook
iPierian on Facebook
YouTube
iPierian on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Nancy Stagliano
  Nancy Stagliano LinkedIn Profile  Nancy Stagliano Twitter Account  Nancy Stagliano News  Nancy Stagliano on Facebook
VP - Bus. Development
Adam Rosenthal
  Adam Rosenthal LinkedIn Profile  Adam Rosenthal Twitter Account  Adam Rosenthal News  Adam Rosenthal on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/4/2013: PaperShare venture capital transaction
Next: 9/4/2013: Thermalin Diabetes venture capital transaction

 

Share this article

 

About Database of VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.